Clinical reference Biomarker Directory
Back to directory

Epstein-Barr virus capsid antigen antibody

Established

EBV VCA antibodies help diagnose mononucleosis and support nasopharyngeal carcinoma evaluation in endemic regions.

Also known as EBV VCA antibody EBV IgM/IgG
In plain language

This antibody test shows whether someone has been exposed to the virus that causes mono. Depending on which type of antibody is found, it can mean a current infection or one from years ago. In certain parts of the world, this virus is also linked to a specific type of nose/throat cancer.

Biomarker & context

Epstein-Barr virus (EBV) viral capsid antigen (VCA) antibodies are produced in response to EBV infection, the cause of infectious mononucleosis and a contributing factor in certain cancers, particularly nasopharyngeal carcinoma.

What it indicates

Interpretation depends on which antibody class is measured: IgM VCA indicates recent/acute infection (mononucleosis), while IgG VCA persists for life after past infection, so a positive result alone doesn't distinguish current illness from prior exposure without considering the specific antibody pattern.

Diagnosis & clinical testing

Measured via serum immunoassay panel (VCA-IgM, VCA-IgG, plus EBNA antibodies to help stage infection timing); elevated EBV antibody titers are used as supportive, not diagnostic, evidence in nasopharyngeal carcinoma workups, particularly in endemic regions (Southeast Asia, Southern China).

Guiding treatment

In suspected nasopharyngeal carcinoma, especially in endemic populations, EBV serology supports but does not replace tissue biopsy and EBV DNA quantification for diagnosis and treatment monitoring.

Clinical significance

IgM versus IgG pattern is essential for correctly timing infection; supportive, not definitive, for cancer diagnosis.

References
  1. General virology and oncology reference literature on EBV serology interpretation and its association with nasopharyngeal carcinoma.